Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.
2.
3.

VACURG studies of post-prostatectomy survival.

Byar DP.

Scand J Urol Nephrol Suppl. 1980;55:113-6.

PMID:
6938013
4.

An analysis of the effects of changes from the assigned treatment in a clinical trial of treatment for prostatic cancer.

Hurst KS, Byar DP.

J Chronic Dis. 1973 May;26(5):311-24. No abstract available.

PMID:
4578154
5.

Treatment of localized prostatic cancer. Radical prostatectomy versus placebo. A 15-year follow-up.

Madsen PO, Graversen PH, Gasser TC, Corle DK.

Scand J Urol Nephrol Suppl. 1988;110:95-100. No abstract available.

PMID:
3187435
6.

The role of radical prostatectomy in the management of stage B adenocarcinoma of the prostate.

Lepor H, Walsh PC.

Prog Clin Biol Res. 1987;243B:343-56. Review. No abstract available.

PMID:
3309989
7.

[Clinical investigation of prostatic cancer patients who underwent radical prostatectomy: analysis of patients in the Tokai Urological Cancer Registry].

Hayashi N, Kawamura J, Fujita K, Naide Y, Kobayashi H, Isogai K, Sudoko H, Miyake K.

Hinyokika Kiyo. 1997 Jul;43(7):471-6. Japanese.

8.

Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.

Cheng L, Poulos CK, Pan CX, Jones TD, Daggy JK, Eble JN, Koch MO.

J Urol. 2005 Sep;174(3):898-902.

PMID:
16093983
9.
10.

Evaluation and management of early stages of carcinoma of prostate.

Hackler RH, Texter JH Jr.

Urology. 1980 Apr;15(4):329-34. No abstract available.

PMID:
7394955
11.

The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy.

Cheng L, Koch MO, Juliar BE, Daggy JK, Foster RS, Bihrle R, Gardner TA.

J Clin Oncol. 2005 May 1;23(13):2911-7.

PMID:
15860849
12.
13.
14.

Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities.

Akakura K, Isaka S, Akimoto S, Ito H, Okada K, Hachiya T, Yoshida O, Arai Y, Usami M, Kotake T, Tobisu K, Ohashi Y, Sumiyoshi Y, Kakizoe T, Shimazaki J.

Urology. 1999 Aug;54(2):313-8.

PMID:
10443731
15.
16.

Radical prostatectomy and early adjuvant hormonal therapy for pTxN+ adenocarcinoma of the prostate.

Seay TM, Blute MC, Zincke H.

Urology. 1997 Dec;50(6):833-7. Review. No abstract available.

PMID:
9426709
17.
18.

[Localized prostatic adenocarcinoma: role of pelvic radiotherapy following radical prostatectomy].

Mazeron JJ, Bolla M.

Cancer Radiother. 1997;1(5):423-30. Review. French.

PMID:
9587372
19.

Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.

Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, Koch MO.

J Urol. 2005 Dec;174(6):2181-5.

PMID:
16280760
20.

Prevalence of silent prostatic adenocarcinoma in 165 patients undergone cystoprostatectomy: a retrospective study.

Cindolo L, Benincasa G, Autorino R, Domizio S, De Rosa G, Testa G, D'Armiento M, Altieri V.

Oncol Rep. 2001 Mar-Apr;8(2):269-71.

PMID:
11182038

Supplemental Content

Support Center